Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 4 2Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Neoplasm Metastasis 3Pain 2Breast Neoplasms 2Bone Neoplasms 2Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Morphine 6Analgesia 6nabiximols 3Pregabalin 3Oxycodone 3Fentanyl 3ziconotide 2Surveys and Questionnaires 2Saline Solution 2Radiofrequency Ablation 2Methadone 2Lidocaine 2Ketamine 2Ibandronic Acid 2Gemcitabine 2Duloxetine Hydrochloride 2Docetaxel 2Botulinum Toxins, Type A 2trimebutine 3-thiocarbamoylbenzenesulfonate 1tanezumab 1tandutinib 1siltuximab 1resiniferatoxin 1incobotulinumtoxinA 1imisopasem manganese 1fulranumab 1erenumab 1cyclobenzaprine 1caffeine, sodium benzoate drug combination 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pain × Ibandronic Acid × Clear all
NCT00478270 2017-08-16

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.

Hoffmann-La Roche

Phase 2 Withdrawn
Sarcoma

Bone Neoplasms, Neoplasm Metastasis, Pain

NCT00502736 2014-01-22

A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.

Hoffmann-La Roche

Phase 2 Completed
13 enrolled
Sarcoma

Bone Neoplasms, Neoplasm Metastasis, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡